Plasmatic dimethylarginines, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) are considered biomarkers of endothelial and renal dysfunction, respectively, in humans. We hypothesize that plasmatic concentration of dimethylarginines in dogs with myxomatous mitral valve disease (MMVD) is influenced by heart disease stage. Eighty-five client-owned dogs with MMVD, including 39, 19, and 27 dogs in ACVIM stages B1, B2, and C+D, respectively, and a control group of 11 clinically healthy dogs were enrolled. A prospective, multicentric, case-control study was performed. Each dog underwent a complete clinical examination, arterial blood pressure measurement, thoracic radiography, six-lead standard electrocardiogram, transthoracic echocardiography, CBC, biochemical profile, and urinalysis. Plasmatic concentration of dimethylarginines was determined through high-performance liquid chromatography coupled with tandem mass spectrometry. Median ADMA was significantly increased in dogs of group C+D (2.5 μmol/L [2.1–3.0]) compared to those of group B1 (1.8 μmol/L [1.6–2.3]; p < 0.001) and healthy dogs (1.9 μmol/L [1.7–2.3]; p = 0.02). Median SDMA was significantly increased in dogs of group C+D (0.7 μmol/L [0.5–0.9]) compared to those of groups B1 (0.4 μmol/L [0.3–0.5]; p < 0.001), B2 (0.4 μmol/L [0.3–0.6]; p < 0.01), and the control group (0.4 μmol/L [0.35–0.45]; p = 0.001). In the final multivariable analysis, ADMA and SDMA were significantly associated with left atrium to aorta ratio (p < 0.001), and creatinine (p < 0.001), respectively. Increased plasmatic concentrations of dimethylarginines suggest a possible role as biomarkers of disease severity in dogs with decompensated MMVD.

血浆二甲基精氨酸、不对称二甲基精氨酸 (ADMA) 和对称二甲基精氨酸 (SDMA) 分别被认为是人类内皮和肾功能障碍的生物标志物。我们假设患有粘液瘤性二尖瓣疾病 (MMVD) 的狗的二甲基精氨酸血浆浓度受心脏病阶段的影响。85只客户拥有的MMVD犬，包括分别处于ACVIM B1、B2和C+D期的39、19和27只犬，以及11只临床健康犬作为对照组。进行了一项前瞻性、多中心、病例对照研究。每只狗都接受了完整的临床检查、动脉血压测量、胸片、六导标准心电图、经胸超声心动图、CBC、生化分析和尿液分析。二甲基精氨酸的血浆浓度通过高效液相色谱与串联质谱联用测定。与 B1 组（1.8 μmol/L [1.6-2.3]）相比，C+D 组犬的 ADMA 中位数显着增加（2.5 μmol/L [2.1-3.0]）；磷 < 0.001) 和健康犬 (1.9 μmol/L [1.7–2.3]; 磷= 0.02）。与 B1 组 (0.4 μmol/L [0.3-0.5]) 相比，C+D 组 (0.7 μmol/L [0.5-0.9]) 犬的中位 SDMA 显着增加；磷 < 0.001), B2 (0.4 μmol/L [0.3–0.6]; 磷 < 0.01), 和对照组 (0.4 μmol/L [0.35–0.45]; 磷= 0.001）。在最终的多变量分析中，ADMA 和 SDMA 与左心房与主动脉比显着相关。磷 < 0.001) 和肌酐 (磷< 0.001)，分别。二甲基精氨酸的血浆浓度增加表明其可能作为失代偿 MMVD 犬疾病严重程度的生物标志物。